Bone evaluation of maxilla-mandibular complex of rats treated with bisphosphonates and corticosteroid associated

• Grant number: 11/20633-2
• Support Opportunities: Regular Research Grants
• Start date: February 01, 2012
• End date: January 31, 2014
• Field of knowledge: Health Sciences - Pharmacy - Medicines Analysis and Control
• Principal Investigator: Marco Vinícius Chaud
• Grantee: Marco Vinícius Chaud
• Host Institution: Pró-Reitoria Acadêmica. Universidade de Sorocaba (UNISO). Sorocaba , SP, Brazil
• Associated researchers: Halbert Villalba ; Liliane Cristine Ferreira de Souza ; Perla Porto Leite Shitara

Abstract

Bone tissue is composed mainly of phosphate and calcium form of hydroxyapatite crystals, incorporanting ions and salts in its structure, being in constant renovation. The Bisphosphonates (BP) are synthetic analogs of pyrophosphate inorganic and present in their chemical structure two phosphate groups (PO3), covalently bonded to a carbon central, plus two chains generically R1 and R2. BP are available in the market management intravenous and oral. The BP is primarily used oral in the treatment of osteoporosis, but there are other less commom indicatons such as Paget's diaseases and osteogenesis Imperfect. The BP intravenous are indicated for the treatment of hypercalcemia associated with multiple myeloma and solid tumor with bone metastasis (breast, prostate and lung). The BP intravenous are effective in prevention and reduction of hypercalcemia in the stabilization of pathology and prevention of bone fractures. Although all BP benefits of therapy, these drugs have been associated, since 2003, a debilitating complication affects the jaw and the jaw called osteonecrosis of the jaws. (AU)